$28.89+0.21%Close 13 Nov 2026
About Pfizer
Pfizer Inc. is a research-based, global biopharmaceutical company that discovers, develops, manufactures, markets, sells and distributes biopharmaceutical products. Its Biopharma segment, the only reportable segment, covers medicines and vaccines across oncology, internal medicine, vaccines, and inflammation and immunology, including biosimilars and off-patent sterile injectables. The company sells to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies, and its vaccines are sold in the U.S. primarily to the federal government. Pfizer operates across developed and emerging markets and supplies its medicines and vaccines to approximately 200 countries and territories. Revenues from outside the U.S. were $25.5 billion in 2025.
A summary of the business section of the company's latest annual report, filed 26 Feb 2026.
Company facts
| Ticker | PFE · NYSE |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Pharmaceuticals |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 78003 |
|---|
| Latest annual report | 10-K, filed 26 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Albert Bourla, DVM, Ph.D. | Chairman & CEO · Director | 379K · < 1% | Open-market purchase, 12 Aug 2026 |
|---|
| Douglas M. Lankler | Executive Vice President | 161K · < 1% | Shares withheld for tax, 25 Feb 2026 |
|---|
| Ronald E. Blaylock | Director | 32.5K · < 1% | Open-market purchase, 5 Aug 2026 |
|---|
| Mortimer J. Buckley | Director | 0 · < 1% | Open-market purchase, 5 Aug 2026 |
|---|
| DAMICO JENNIFER B. | SVP & Controller | — | Open-market sale, 5 Aug 2026 |
|---|
| McDermott Michael | Executive Vice President | — | Shares withheld for tax, 26 Feb 2026 |
|---|
| SAHNI PAYAL | Executive Vice President | — | Shares withheld for tax, 25 Feb 2026 |
|---|
| Fonseca Lidia | Executive Vice President | — | Option exercise, 25 Feb 2026 |
|---|
| BOSHOFF CHRISTOFFEL | President, R&D | — | Shares withheld for tax, 25 Feb 2026 |
|---|
| SUSMAN SALLY | Executive Vice President | — | Option exercise, 27 Feb 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
PFE in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.